A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
Herthena-Lung02 data are an ASCO shocker.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
